EA202190557A1 - СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА - Google Patents

СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА

Info

Publication number
EA202190557A1
EA202190557A1 EA202190557A EA202190557A EA202190557A1 EA 202190557 A1 EA202190557 A1 EA 202190557A1 EA 202190557 A EA202190557 A EA 202190557A EA 202190557 A EA202190557 A EA 202190557A EA 202190557 A1 EA202190557 A1 EA 202190557A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazo
pyrrolidin
benzamide
amino
pyrazin
Prior art date
Application number
EA202190557A
Other languages
English (en)
Russian (ru)
Inventor
Пол Аллен Бетел
Лай Чунь Чань
Кейти Грейс Купер
Роберт Джон Кокс
Майкл Дэвид Голден
Шон Алан Хьюс
Люсинда Виктория Джексон
Кирсти Джейн Миллард
Эндрю Джон Филлипс
Александр Джеймс Телфорд
Джерри Эвартс
Майкл Джозеф Лоулер
Реми Е.Дж.Н. Литйенс
Петер Йоаннес Серваас Савио Ван Эийк
Матильда Мария Генрика Ферстаппен
Франк Л.М. Вос
Эрик Юррин Зейп
Цю Цзюньин
Аньган Ван
Рустам Фердинанд Гэррей
Дэвид Аллен Шорт
Original Assignee
Асерта Фарма Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Асерта Фарма Б.В. filed Critical Асерта Фарма Б.В.
Publication of EA202190557A1 publication Critical patent/EA202190557A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EA202190557A 2018-08-29 2019-08-28 СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА EA202190557A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724228P 2018-08-29 2018-08-29
PCT/EP2019/072991 WO2020043787A1 (en) 2018-08-29 2019-08-28 Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide

Publications (1)

Publication Number Publication Date
EA202190557A1 true EA202190557A1 (ru) 2021-07-13

Family

ID=67928802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190557A EA202190557A1 (ru) 2018-08-29 2019-08-28 СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА

Country Status (16)

Country Link
US (3) US12024520B2 (cg-RX-API-DMAC10.html)
EP (1) EP3844149A1 (cg-RX-API-DMAC10.html)
JP (3) JP7439095B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250119664A (cg-RX-API-DMAC10.html)
CN (2) CN112638878B (cg-RX-API-DMAC10.html)
AU (4) AU2019332882B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021003480A2 (cg-RX-API-DMAC10.html)
CA (1) CA3109734A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021003676A2 (cg-RX-API-DMAC10.html)
EA (1) EA202190557A1 (cg-RX-API-DMAC10.html)
IL (3) IL281025B2 (cg-RX-API-DMAC10.html)
MA (1) MA53485A (cg-RX-API-DMAC10.html)
MX (2) MX2021002246A (cg-RX-API-DMAC10.html)
MY (1) MY206899A (cg-RX-API-DMAC10.html)
WO (1) WO2020043787A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202306381B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
EP3947386A1 (en) * 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
DK4054582T3 (da) 2019-11-04 2025-12-01 Astrazeneca Ab Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
CR20230018A (es) 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
CN103889987B (zh) * 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
CN107056786B (zh) 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
ES2856248T3 (es) 2016-12-21 2021-09-27 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
CN107522701B (zh) 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
US11161851B2 (en) 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法

Also Published As

Publication number Publication date
CA3109734A1 (en) 2020-03-05
MX2023011692A (es) 2023-10-19
US20240317766A1 (en) 2024-09-26
JP2026021364A (ja) 2026-02-10
KR20210053304A (ko) 2021-05-11
AU2023204660A1 (en) 2023-08-03
IL322382A (en) 2025-09-01
AU2023204660B2 (en) 2024-01-25
WO2020043787A1 (en) 2020-03-05
IL281025B1 (en) 2024-08-01
JP2024037935A (ja) 2024-03-19
US12448387B2 (en) 2025-10-21
AU2022200828B2 (en) 2023-05-25
KR102842131B1 (ko) 2025-08-04
CN112638878A (zh) 2021-04-09
JP2021535220A (ja) 2021-12-16
CN112638878B (zh) 2025-07-22
KR20250119664A (ko) 2025-08-07
IL281025A (en) 2021-04-29
JP7829541B2 (ja) 2026-03-13
AU2024202290A1 (en) 2024-05-02
US12024520B2 (en) 2024-07-02
MX2021002246A (es) 2021-05-27
IL312413A (en) 2024-06-01
CN120904205A (zh) 2025-11-07
US20260109701A1 (en) 2026-04-23
MA53485A (fr) 2021-12-08
IL312413B1 (en) 2025-09-01
ZA202306381B (en) 2024-11-27
ZA202409391B (en) 2025-04-30
CO2021003676A2 (es) 2021-04-08
AU2022200828A1 (en) 2022-03-03
EP3844149A1 (en) 2021-07-07
JP7439095B2 (ja) 2024-02-27
BR112021003480A2 (pt) 2021-05-18
AU2019332882A1 (en) 2021-04-22
AU2019332882B2 (en) 2022-01-27
IL312413B2 (en) 2026-01-01
MY206899A (en) 2025-01-13
US20220127270A1 (en) 2022-04-28
IL281025B2 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
ZA202409391B (en) Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
MX385054B (es) Piridinas sustituidas con heteroarilo y metodos de uso.
MX2014013924A (es) Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida.
MX394953B (es) Proceso para la preparación de compuestos de 2,3-dihidrotiazolo[3,2-a]pirimidin-4-io ópticamente activo.
CR20200154A (es) Enantiómeros de tiazoles sustituidos como compuestos antivirales
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
EA201891772A1 (ru) Трифторацетатная соль агониста tlr7 и ее кристаллическая форма b, способы получения и использование
EA201400089A1 (ru) Конститутивно активные мутанты рецептора абк (абсцизовой кислоты)
MY195169A (en) Cyclic Ether Derivatives of Pyrazolo[1,5-A]Pyrimidine-3-Carboxyamide
MX376029B (es) Compuestos de isoindol.
PH12021553263A1 (en) Pyrazolopyrimidine compound, preparation method for same and applications thereof
PH12018502614A1 (en) Preparation of factor xa derivatives
MX375384B (es) Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4-cianofenil)urea maleato.
IN2014KN02722A (cg-RX-API-DMAC10.html)
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
MX2020006641A (es) Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
WO2020053795A3 (en) Process for the preparation of acalabrutinib and its intermediates
EA202192840A1 (ru) Способ получения соединений карбамоилоксиметилтриазолциклогексиловой кислоты
JOP20190223A1 (ar) عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
RU2012131901A (ru) Способ изготовления абразивного инструмента